论文部分内容阅读
目的评价加替沙星与左氧氟沙星治疗泌尿系统感染的临床安全性、有效性,及疗效与成本。方法检索1998年1月-2016年4月在Pub Med、Cochrane图书馆、中国期刊全文数据库(CNKI)、万方数据库、中文科技期刊全文数据库(VIP)、中国生物医学文献数据库(CBM)发表的有关加替沙星与左氧氟沙星治疗泌尿系统感染的文献,按照Cochrane系统评价方法,运用Rev Man 4.2.10软件进行Meta分析。结果纳入文献17篇,共1 348例;加替沙星治疗泌尿系统感染的有效性明显高于左氧氟沙星[RR=2.01,95%CI(1.44、2.79)],疗程与不良反应无差异[RR=0.76,95%CI(0.50、1.17),P=0.22],但加替沙星治疗泌尿系统感染的成本–效果明显低于左氧氟沙星。结论目前泌尿系统感染的治疗方案中,尽管左氧氟沙星的疗效稍逊色于加替沙星,但左氧氟沙星更具成本–效果优势。
Objective To evaluate the clinical safety, efficacy, efficacy and cost of gatifloxacin and levofloxacin in the treatment of urinary tract infections. Methods The data of PubMed, Cochrane Library, CNKI, Wanfang Database, VIP, and CBM were searched from January 1998 to April 2016. The literature on gatifloxacin versus levofloxacin in the treatment of urinary tract infections was analyzed by Meta-analysis using the Rev Man 4.2.10 software in accordance with the Cochrane systematic review. Results 17 articles were included in the literature, of which 1 348 in total. The efficacy of gatifloxacin in the treatment of urinary tract infection was significantly higher than that of levofloxacin (RR = 2.01, 95% CI 1.44, 2.79) 0.76, 95% CI (0.50, 1.17), P = 0.22], but the cost-effectiveness of gatifloxacin in the treatment of urinary tract infections was significantly lower than that of levofloxacin. CONCLUSIONS Currently, levofloxacin is more cost-effective than lefloxacin in the treatment of urinary tract infections, although levofloxacin is less effective than gatifloxacin.